-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Capricor Therapeutics Analyst Ratings
Capricor Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/04/2023 | 1370.59% | HC Wainwright & Co. | $18 → $40 | Maintains | Buy |
| 08/15/2023 | 561.76% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 03/16/2023 | 561.76% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 10/26/2022 | 451.47% | Ladenburg Thalmann | → $15 | Initiates Coverage On | → Buy |
| 01/31/2022 | 561.76% | HC Wainwright & Co. | $14 → $18 | Maintains | Buy |
| 10/11/2021 | 414.71% | HC Wainwright & Co. | $9 → $14 | Maintains | Buy |
| 07/15/2019 | 355.88% | HC Wainwright & Co. | $3.5 → $12.4 | Maintains | Buy |
| 12/31/2018 | 28.68% | HC Wainwright & Co. | $8.6 → $3.5 | Maintains | Buy |
What is the target price for Capricor Therapeutics (CAPR)?
The latest price target for Capricor Therapeutics (NASDAQ: CAPR) was reported by HC Wainwright & Co. on October 4, 2023. The analyst firm set a price target for $40.00 expecting CAPR to rise to within 12 months (a possible 1370.59% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Capricor Therapeutics (CAPR)?
The latest analyst rating for Capricor Therapeutics (NASDAQ: CAPR) was provided by HC Wainwright & Co., and Capricor Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Capricor Therapeutics (CAPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on October 4, 2023 so you should expect the next rating to be made available sometime around October 4, 2024.
Is the Analyst Rating Capricor Therapeutics (CAPR) correct?
While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a maintained with a price target of $18.00 to $40.00. The current price Capricor Therapeutics (CAPR) is trading at is $2.72, which is out of the analyst's predicted range.
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/04/2023 | 1370.59% | HC Wainwright & Co. | $18 → $40 | Maintains | Buy |
| 08/15/2023 | 561.76% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 03/16/2023 | 561.76% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 10/26/2022 | 451.47% | Ladenburg Thalmann | → $15 | Initiates Coverage On | → Buy |
| 01/31/2022 | 561.76% | HC Wainwright & Co. | $14 → $18 | Maintains | Buy |
| 10/11/2021 | 414.71% | HC Wainwright & Co. | $9 → $14 | Maintains | Buy |
| 07/15/2019 | 355.88% | HC Wainwright & Co. | $3.5 → $12.4 | Maintains | Buy |
| 12/31/2018 | 28.68% | HC Wainwright & Co. | $8.6 → $3.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/04/2023 | 1370.59% | HC Wainwright公司 | $18→$40 | 維護 | 買 |
| 2023年08月15日 | 561.76% | HC Wainwright公司 | →$18 | 重申 | 購買→購買 |
| 03/16/2023 | 561.76% | HC Wainwright公司 | →$18 | 重申 | →購買 |
| 10/26/2022 | 451.47% | 拉登堡·塔爾曼 | →$15 | 開始承保 | →購買 |
| 2022年1月31日 | 561.76% | HC Wainwright公司 | $14→$18 | 維護 | 買 |
| 10/11/2021 | 414.71% | HC Wainwright公司 | $9→$14 | 維護 | 買 |
| 2019年07月15日 | 355.88% | HC Wainwright公司 | $3.5→$12.4 | 維護 | 買 |
| 2018年12月31日 | 28.68% | HC Wainwright公司 | $8.6→$3.5 | 維護 | 買 |
What is the target price for Capricor Therapeutics (CAPR)?
Capricor Treateutics(CAPR)的目標價格是多少？
The latest price target for Capricor Therapeutics (NASDAQ: CAPR) was reported by HC Wainwright & Co. on October 4, 2023. The analyst firm set a price target for $40.00 expecting CAPR to rise to within 12 months (a possible 1370.59% upside). 4 analyst firms have reported ratings in the last year.
納斯達克(納斯達克代碼：CAPR)的最新目標價是由HC Wainwright&Co.於2023年10月4日報道的。這家分析公司將目標價定為40美元，預計CAPR將在12個月內升至(可能上漲1370.59%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Capricor Therapeutics (CAPR)?
Capricor Treateutics(CAPR)的最新分析師評級是什麼？
The latest analyst rating for Capricor Therapeutics (NASDAQ: CAPR) was provided by HC Wainwright & Co., and Capricor Therapeutics maintained their buy rating.
納斯達克公司(納斯達克代碼：CAPR)的最新分析師評級由HC Wainwright&Co.提供，Capricor治療公司維持買入評級。
When is the next analyst rating going to be posted or updated for Capricor Therapeutics (CAPR)?
Capricor Treeutics(CAPR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on October 4, 2023 so you should expect the next rating to be made available sometime around October 4, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Capricor Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Capricor治療公司的上一次評級是在2023年10月4日提交的，所以你應該預計下一次評級將在2024年10月4日左右的某個時候提供。
Is the Analyst Rating Capricor Therapeutics (CAPR) correct?
分析師對Capricor Treeutics(CAPR)的評級正確嗎？
While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a maintained with a price target of $18.00 to $40.00. The current price Capricor Therapeutics (CAPR) is trading at is $2.72, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Capricor Treateutics(CAPR)評級保持不變，目標價在18.00美元至40.00美元之間。Capricor Treateutics(CAPR)目前的交易價格為2.72美元，超出了分析師的預測範圍。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧